Evaluation of off-label medication use and drug safety in a pediatric intensive care unit
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Soojin | - |
dc.contributor.author | Yang, Mi Hee | - |
dc.contributor.author | Kim, Jung Sun | - |
dc.contributor.author | Cho, Yoonsuk | - |
dc.contributor.author | Choi, Nigh | - |
dc.contributor.author | Cho, Eun Jung | - |
dc.contributor.author | Park, June Dong | - |
dc.contributor.author | Choi, Yu Hyeon | - |
dc.contributor.author | Choi, Kyung Hee | - |
dc.date.accessioned | 2023-09-10T01:40:09Z | - |
dc.date.available | 2023-09-10T01:40:09Z | - |
dc.date.created | 2023-08-03 | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1319-0164 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89078 | - |
dc.description.abstract | Safety and efficacy are essential in the process of disease treatment. However, off-label medication use is inevitable because various medications do not contain regulatory labels for pediatric use. We aimed to examine off-label medication use and analyze the risk factors correlated with adverse drug reactions (ADRs). This study was performed retrospectively using electronic medical data from a pediatric intensive care unit (PICU) of a tertiary hospital in Korea from July 2019 to June 2020. A total 6,183 prescribed medications from 502 PICU patients were examined in the present study. A total of 80% were infants or children, and 96.0% of them were treated with off-label medications. It was discovered that 4,778 off-label cases (77.2%) of the top 100 drugs had prescriptions with dosage (67.8%). Drugs prescribed to patients admitted to the cardiothoracic department (odds ratio [OR], 3.248; p = 0.019), total number of medications (OR, 1.116; p = 0.001), and length of PICU stay of ≥ 7 days (OR, 4.981; p = 0.008) were significantly associated with ADRs. ADRs were noted to be more severe in off-label use (p = 0.0426). For appropriate medication use, evidence regarding the safety of off-label medications is required and ultimately reflected in the official regulation. © 2023 The Author(s) | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | Saudi Pharmaceutical Journal | - |
dc.title | Evaluation of off-label medication use and drug safety in a pediatric intensive care unit | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 001057408700001 | - |
dc.identifier.doi | 10.1016/j.jsps.2023.101704 | - |
dc.identifier.bibliographicCitation | Saudi Pharmaceutical Journal, v.31, no.9 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85165616306 | - |
dc.citation.title | Saudi Pharmaceutical Journal | - |
dc.citation.volume | 31 | - |
dc.citation.number | 9 | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Hee | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Adverse drug reactions | - |
dc.subject.keywordAuthor | Drug labeling | - |
dc.subject.keywordAuthor | Off-label use | - |
dc.subject.keywordAuthor | Patient safety | - |
dc.subject.keywordAuthor | Pediatric Intensive Care Units | - |
dc.subject.keywordAuthor | Pediatrics | - |
dc.subject.keywordPlus | HOSPITALIZED CHILDREN | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | WARDS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.